ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumours and improves symptoms
A multicenter Phase II clinical trial has demonstrated significant tumour shrinkage and disease control in patients…
Browsing: Featured
ESMO 2025: Novel treatment combination improves progression-free survival in metastatic, oestrogen-receptor-positive HER-2-negative breast cancer
Patients with oestrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with…
ESMO 2025: Chemo combination boosts overall survival in patients with EGFR-mutant NSCLC
Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful…
ESMO 2025: Immunotherapy after surgery shows promise in treating rare, aggressive skin cancer
A drug that harnesses the immune system to attack cancer cells has proved successful in…
Velcro-like pan-cancer immunotherapy destroys tumours
A new, highly potent class of immunotherapeutics with unique Velcro-like binding properties can kill diverse…
Fat tissue’s hidden role in ovarian cancer spread
In a new study published in Nature Communications, researchers at Karolinska Institutet and Queen Mary…
AGITG ASM 2025: Special Podcast Preview
A sneak preview podcast of what to expect from the AGITG’s 2025 ASM!
Study finds melanoma less common in individuals with several tattoos
People with more than one tattoo session may have a decreased risk of the skin…
Distribution of fat could influence cancer risk, study suggests
How fat is distributed in people’s bodies could make a difference to their risk of…
Access gap widens: only one in 65 Australian cancer survivors can enrol in oncology rehab
The number of cancer rehabilitation programmes in Australia has more than doubled in the past…